BiotechTube

Desidustat Oral Tablet + Darbepoetin Alfa

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Chronic Kidney Disease Stage 3

Conditions

Chronic Kidney Disease Stage 3, Anemia, Chronic Kidney Disease Stage 4, Chronic Kidney Disease Stage 5

Trial Timeline

Jul 20, 2019 → Aug 25, 2021

NCT ID
NCT04012957

About Desidustat Oral Tablet + Darbepoetin Alfa

Desidustat Oral Tablet + Darbepoetin Alfa is a phase 3 stage product being developed by Zydus Lifesciences for Chronic Kidney Disease Stage 3. The current trial status is completed. This product is registered under clinical trial identifier NCT04012957. Target conditions include Chronic Kidney Disease Stage 3, Anemia, Chronic Kidney Disease Stage 4.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT04012957Phase 3Completed

Competing Products

20 competing products in Chronic Kidney Disease Stage 3

See all competitors
ProductCompanyStageHype Score
macitentan 10 mgBML, Inc.Phase 3
76
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
47
TERN-701Terns PharmaceuticalsPhase 1/2
38
Fludarabine + Cyclophosphamide + PRGN-3007PrecigenPhase 1
28
LY3556050 + PlaceboEli LillyPhase 2
52
THB001Third Harmonic BioPhase 1
25
BriquilimabJasper TherapeuticsPhase 1/2
33
BriquilimabJasper TherapeuticsPhase 1/2
33
BriquilimabJasper TherapeuticsPhase 2
44
Empagliflozin + Matching placeboEli LillyPhase 3
77
LY3461767 + PlaceboEli LillyPhase 1
33
Pirtobrutinib + Venetoclax + RituximabEli LillyPhase 3
77
LY3526318 + PlaceboEli LillyPhase 2
52
PirtobrutinibEli LillyPhase 2
52
Ibrutinib + LY3214996Eli LillyPhase 1
33
Pirtobrutinib + AcalabrutinibEli LillyPhase 2
52
LYR-210Lyra TherapeuticsPhase 2
44
LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2)Lyra TherapeuticsPhase 2
44
480 Mometasone Furoate Sinus Drug DepotLyra TherapeuticsPhase 1
25
LYR-210 + Sham procedure controlLyra TherapeuticsPhase 3
69

Other Products from Zydus Lifesciences

SaroglitazarApproved
85
DesidustatApproved
85
Desidustat Oral Tablet + Epoetin AlfaPhase 3
77
Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel + DUAC® Gel + PlaceboPhase 3
77
Pertuzumab (ZRC-3277) + Pertuzumab (Perjeta®)Phase 3
77